Navigation Links
Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Proposed Dividend
Date:2/12/2008

Adjusted net income excluding selected items(1)

Q4 2007: euro 1,429 million (up 4.5%), i.e. euro 1.07 per share (up 5.9%, or up

18.3% in U.S. dollars(2))

FY 2007: euro 6,961 million (up 5.9%), i.e. euro 5.17 per share (up 5.9%, or up

15.7% in U.S. dollars(2))

BRIDGEWATER, N.J., Feb. 12 /PRNewswire-FirstCall/ -- In order to give a representation of our underlying economic performance, we present and explain an adjusted(1) income statement. We also report adjusted net income and adjusted EPS (excluding selected items) in U.S. dollars(2) in order to facilitate comparisons with the majority of major pharmaceutical groups. The 2007 consolidated income statement is provided in the Appendices. Full-year consolidated net income for 2007 was euro 5,263 million, against euro 4,006 million for 2006.

Fourth quarter

-- Net sales down 2.2% on a comparable basis (or 6.0% on a reported basis)

at euro 6,911 million

-- Growth of 5.7% in pharmaceuticals net sales after excluding the impact

of generics of Ambien(R) IR in the United States and Eloxatin(R) in

Europe(3)

-- Growth in earnings despite the negative effects of the euro/dollar

exchange rate and of earlier shipments of influenza vaccines than in

2006

2007 full year: euro 5.28 adjusted EPS with selected items; euro 5.17 excluding selected items
-- Net sales up 2.8% on a comparable basis (down 1.1% on a reported basis)

at euro 28,052 million

-- Growth of 6.4% in Pharmaceuticals net sales after excluding the impact

of generics of Ambien(R) IR in the United States and Eloxatin(R) in

Europe(3); 14.5% growth in Vaccines net sales

-- Lantus(R): First insulin brand to exceed euro 2 billion of sales

-- Marked decline in selling and general expense
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. Sanofi-Aventis renews licenses for Genomatix chip analysis pipeline
2. Sanofi-aventis US Chairman Tim Rothwell Addresses CMSAs Collaborative Practice Summit
3. Sanofi-aventis Announces a Good Third Quarter Performance; Increase in 2007 full-year earnings growth guidance
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Texas (PRWEB) December 19, 2014 ... exhibited at the AMSUS Society for Federal Health ... the locum tenens industry to military and federal ... attended the National Veterans Small Business Engagement (NVSBE) ... Tenens continues to be a vital solution in ...
(Date:12/19/2014)... Dec. 18, 2014 (HealthDay News) -- A new study ... moderate to severe hot flashes and night sweats -- ... Hot flashes are common during menopause, affecting about ... also affect women after menopause, since they then face ... "Our findings suggest women who exhibit moderate or severe ...
(Date:12/19/2014)... Randy Dotinga HealthDay Reporter ... painkillers, including ibuprofen, might slightly reduce your risk of ... Use of ibuprofen (Advil, Motrin) and naproxen (Aleve) appear ... by 15 percent, the researchers concluded after reviewing nine ... by sun exposure. These painkillers "have ...
(Date:12/19/2014)... Reinberg HealthDay Reporter THURSDAY, ... on one leg for at least 20 seconds you may ... Difficulty standing on one leg may indicate that small strokes ... for more serious strokes is high, the investigators reported online ... showing instability while standing on one leg, as well as ...
(Date:12/17/2014)... Mass. (PRWEB) December 17, 2014 ... of Osteopathic Medicine (ACOM), which welcomed its inaugural ... Desktop Infrastructure (VDI) to seamlessly support bring your ... – and teaching – experience. The solution, comprised ... NetScaler , Dell server and storage infrastructure ...
Breaking Medicine News(10 mins):Health News:Consilium Staffing Increasing Awareness of Locum Tenens through Conference Appearances 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3
... issued Global Air Quality Guidelines on Thursday so as to ... each year with most of the deaths occurring in developing ... air quality in the cities. A statement issued by the ... could be saved every year by bringing down the PM10 ...
... in Andhra Pradesh carry the HIV virus, which is passed on ... Society (APSACS) has come to the aid of such infants, suffering ... the society strives to realize infant births sans HIV by the ... the country, the group has lined up the Telugu Network of ...
... (RPCI), the wholly owned subsidiary of Indian pharma major ... with Janssen-Ortho Inc. (JOI) for marketing of its generic ... be commercialised by RPCI, Fentanyl would be sold under ... with Janssen-Ortho Inc, the company said in a statement ...
... and three arms on the Indonesian resort island of Bali ... ,"It's a tough case, but so far they are stable," ... the Bali capital Denpasar, told DPA., ,"We are still ... action yet," he said, adding that in medical terms the ...
... Medical Journal reports that vaccination against the sexually transmitted virus ... in Europe//. ,All the girls of the age ... GlaxoSmithKline or with Gardasil of Merck & Co., according to ... in the U.S. in which, a bill passed by the ...
... Australia are going full steam to counter skin diseases ... aim to prevent the spread of tinea(fungal infections),scabies and ... the ,far flung interior aboriginal communities and to mete ... , ,Poverty and unhygienic living conditions facilitate the ...
Cached Medicine News:
(Date:12/17/2014)... Dec. 17, 2014 With advancements in ... MRI market is seeing new growth, according to ... scans account for the majority of market volume, ... of images, which are creating opportunities for more sophisticated ... is growing at a rate of 4%, with ...
(Date:12/17/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... enrollment in its first Phase 2a study, RXI-109-1301.  ... the 1-month findings that were reported in September ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and ... addition of the "Electrocardiogram (ECG) Devices - Global ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... reach US$330 million by 2016. The North ... the global market share while Europe ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
... 29 AstraZeneca (NYSE: AZN ) announced today ... Delaware , has found that the substance patent protecting CRESTOR (RE37,314 – the ... no inequitable conduct was committed by any Shionogi employee. The court also held ... , , ...
... CINCINNATI, Ohio , June 29 Dr. Harry ... invited speaker and panel discussion participant at the 2010 Central Regional Meeting ... June 16-19, 2010 .  The 2010 CeRMACS attracted over 400 participants ... traditional chemical disciplines.   , , ...
Cached Medicine Technology:CRESTOR® Patent Upheld By US Court 2CRESTOR® Patent Upheld By US Court 3Dr. Harry J. Guttman, Esq. Invited Speaker at 2010 Central Regional Meeting of the American Chemical Society 2
... access. Hollow stylet design with ... with two-part needle. Initial flashback ... maintaining thumb position on stylet. ... of the stylet. Supplied sterile ...
Used for arterial and venous punctures. The tapered hub design of the catheter facilitates wire guide introduction. Supplied sterile in peel-open packages. Intended for one-time use....
Used for placement of .035 inch (0.89 mm) or .038 inch (0.97 mm) diameter wire guides into the vascular system when a small 24 gage needle stick is desired....
Used for percutaneous introduction of balloon, electrode and closed or non-tapered end catheters for vascular and non-vascular use....
Medicine Products: